Lendeckel / Hooper Viral Proteases and Antiviral Protease Inhibitor Therapy

Proteases in Biology and Disease
1. Auflage 2009
ISBN: 978-90-481-2348-3
Verlag: Springer Netherland
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 8, 132 Seiten, eBook

Reihe: Proteases in Biology and Disease

The 8 th volume in the Proteases in Biology and Disease series focuses on the role of proteases in virus function and their potential as anti-viral targets. Viral infections are still difficult to threat and some remained life-threatening diseases in spite of antiviral drug research over decades. Proteases are still regarded as an Achilles’ heel of the pathogens and, thus, protease inhibitors may help to handle the known and the emerging viral threads. The book discusses viral proteases of the most important pathogenic viruses, responsible for severe diseases: AIDS, SARS, Hepatitis, Cytomegalovirus, T-cell lymphotropic virus, Picornavirus. This book focuses specifically on the viral proteases, crucial prerequisites for viral entry into cells and viral replication. Viral proteases represent an important pharmaceutical target. The current stage of protease inhibitor development and therapy are summarised and discussed by experts in the field. This volume represents a timely and valuable continuation of the Proteases in Biology and Disease series. The reader will learn the potential for proteases as targets for effective anti-virals. This book will be a valuable source of information on viral proteases and provoke further research in this important field.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Lendeckel, Uwe

Hooper, Nigel M.

Inhaltsverzeichnis

Preface. Contributors. 1.Study of Inhibitors Against SARS Coronavirus by Computational Approaches; Kuo-Chen Chou, Dong-Qing Wei, Qi-Shi Du, Suzanne Sirois, Hong-Bin Shen and Wei-Zhu Zhon. 2. HIV-1 Protease and AIDS Therapy; Irene T. Weber, Ying Zhang, and Jozsef Tozser. 3. Hepatitis C Virus; Philip Tedbury and Mark Harris. 4. Antiviral Activity of Proteasome Inhibitors/Cytomegalovirus; Marion Kaspari and Elke Bogner. 5. Rational Drug Design of HTLV-I Protease Inhibitors; Jeffrey-Tri Nguyen and Yoshiaki Kiso. 6. Picornaviruses; David Neubauer, Jutta Steinberger, and Tim Skern. Index.